Antineoplastics (EGFR inhibitors)
- Target EGFR-driven tumors
- EGFR-mutant NSCLC is the major TKI use
- Osimertinib has strong CNS activity
- Rash + diarrhea are common class effects
- Interstitial lung disease is rare but serious
- Some agents prolong QT
- Tumor mutation determines benefit
Class at a glance
- Target EGFR-driven tumors
Clinical role
- EGFR-mutant NSCLC is the major TKI use
- Osimertinib has strong CNS activity
Safety / monitoring
- Interstitial lung disease is rare but serious
- Some agents prolong QT
- Tumor mutation determines benefit
Safety distinctions
- Rash + diarrhea are common class effects
Self-check
- What clinically distinguishes Osimertinib within Antineoplastics (EGFR inhibitors)?
strong CNS activity.
- What key adverse effect/risk occurs with Antineoplastics (EGFR inhibitors)?
Rash + diarrhea are common class effects.
Drugs in this class (2)
All drug classes · Open the interactive console ↗
